Gyre Therapeutics (GYRE) Receivables (2012 - 2026)

Gyre Therapeutics (GYRE) has reported Receivables for 15 consecutive years, with $26.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 29.22% year-over-year to $26.8 million; the TTM figure through Mar 2026 stood at $26.8 million (up 29.22% YoY), while the FY2025 annual figure was $36.9 million, up 49.1% from the prior year.
• Receivables declined to $26.8 million in Q1 2026 per GYRE's latest filing, from $31.4 million in the prior quarter.
• Across five years, Receivables topped out at $31.4 million in Q4 2025 and bottomed at $564000.0 in Q1 2022.
• Historically, Receivables has averaged $17.3 million across 5 years, with a median of $19.9 million in 2024.
• On a YoY basis, Receivables climbed as much as 842.57% in 2022 and fell as far as 43.94% in 2022.
• Gyre Therapeutics' Receivables stood at $17.1 million in 2022, then declined by 17.96% to $14.1 million in 2023, then jumped by 76.11% to $24.8 million in 2024, then increased by 26.94% to $31.4 million in 2025, then slipped by 14.7% to $26.8 million in 2026.
• Business Quant data shows GYRE's Receivables at $26.8 million in Q1 2026, $31.4 million in Q4 2025, and $26.3 million in Q3 2025.